|
|
- 2018
The surge in biosimilars: considerations for effective pharmacovigilance and EU regulationKeywords: biologics, biosimilars, immunogenicity, interchangeability, pharmacovigilance, regulatory requirements, safety, traceability Abstract: The development of biosimilars is growing rapidly, especially in Europe. They are a cost-effective alternative to original biological medicines and can help improve patient access to these therapies
|
